The incidence of NETs is increasing, with approximately 12,000 new diagnoses in the United States each year.1 The 5-year survival rate of patients with NETs is associated with tumor grades2 determined by the proliferation rate of the neoplastic cells, most commonly by measuring the Ki-67 labeling index (LI).3-5 Accurate grading of NETs is necessary to ensure proper treatment and patient management. The gene discussed is MKI67; the disease is neoplasm.